Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). We are developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist that has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation (FAO), and may increase production of new mitochondria.
We believe REN001 could benefit patients with genetic mitochondrial myopathies who experience weakness, fatigue, cramping, and wasting of muscle due to the mitochondria’s inability to produce adequate levels of ATP. These patients often struggle to perform everyday activities, and over time, are at risk of experiencing cardiac and multisystem morbidities and have reduced life expectancy. We are initially developing REN001 in three rare genetic diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease).
(Note: Reneo Pharmaceuticals priced its IPO on April 8, 2021, at $15 – the bottom of its $15-to-$17 range on 6.25 million shares to raise $93.75 million.)
|Address||12230 El Camino Real, Suite 230 San Diego, California 92130|
|Phone Number||(858) 283-0280|
|View Prospectus:||Reneo Pharmaceuticals|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-19.5 mil (last 12 months)|
|Price range||$15.00 - $15.00|
|Est. $ Volume||$93.8 mil|
|Manager / Joint Managers||Jefferies/ SVB Leerink/ Piper Sandler|
|Expected To Trade:||4/9/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|